BIRMINGHAM, Ala.–(BUSINESS WIRE)–May. 17, 2012– Medical Properties Trust, Inc. (NYSE: MPW) announced today that its Board of Directors declared a regular quarterly cash dividend of $0.20 per share of common stock to be paid on July 12, 2012 to stockholders of record on June 14, 2012.

About Medical Properties Trust, Inc.

Medical Properties Trust, Inc. is a Birmingham, Alabama based self-advised real estate investment trust formed to capitalize on the changing trends in healthcare delivery by acquiring and developing net-leased healthcare facilities. These facilities include inpatient rehabilitation hospitals, long-term acute care hospitals, regional acute care hospitals, ambulatory surgery centers and other single-discipline healthcare facilities, such as heart hospitals and orthopedic hospitals.

The statements in this press release that are forward looking are based on current expectations and actual results or future events may differ materially. Words such as “expects,” “believes,” “anticipates,” “intends,” “will,” “should” and variations of such words and similar expressions are intended to identify such forward-looking statements, which include, but are not limited to, the payment of future dividends, if any. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results of the Company or future events to differ materially from those expressed in or underlying such forward-looking statements, including without limitation: national and economic, business, real estate and other market conditions; the competitive environment in which the Company operates; the execution of the Company’s business plan; financing risks; the Company’s ability to maintain its status as a REIT for federal income tax purposes; acquisition and development risks; potential environmental and other liabilities; and other factors affecting the real estate industry generally or the healthcare real estate in particular. For further discussion of the factors that could affect outcomes, please refer to the “Risk Factors” section of the Company’s Form 10-K, as amended, for the year ended December 31, 2011 and our other SEC filings. Except as otherwise required by the federal securities laws, the Company undertakes no obligation to update the information in this press release.

Source: Medical Properties Trust, Inc.

Medical Properties Trust
Charles Lambert, 205-397-8897
Finance Director
clambert@medicalpropertiestrust.com

Many people spend more time planning their vacation than their estates. Without a comprehensive estate plan, a significant part of the work you’ve done throughout your life can be lost or given to unintended beneficiaries. [Original air date: 5/12/12]

Podcast: Play in new window | Download

A LifeSci Advisors report was recently published. View the PDF here.

There’s a lot of jargon out there in the financial world–and many times, people use words interchangeably that really shouldn’t be. So, the question is: do you have a retirement plan or an investment plan? In this case, they are two VERY different plans. [Original air date: 5/5/12]

Podcast: Play in new window | Download

Shareholders in Hines Real Estate Investment Trust (Hines REIT) will be receiving their 2011 Annual Report in the next few days. View the PDF report here.

We thought you might be interested in Summer Street’s recent report on Rockwell Medical.

Click here for the PDF of the report.

Click here for a PDF of the Hines Global REIT 2011 Annual Report

On Monday, MLV & Co LLC hosted an Expert Physician Conference Call for investors, reviewing the Promacta ENABLE 2 data presented recently at EASL. Their call featured Dr. Nezam H. Afdhal, a world renowned expert in the research and development of new anti-viral therapies for hepatitis. MLV’s report can be found here.

WIXOM, Mich., May 3, 2012 (GLOBE NEWSWIRE) — Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today its results for the first quarter ended March 31, 2012.

First Quarter Financial Highlights

• Sales were $12.0 million compared to $13.3 million first quarter 2011, primarily due to lower international sales.
• Sales increased 1.1% sequentially over the fourth quarter 2011 and gross profit dollars increased 5.3%.
• Gross profit margins improved 1.1 percentage points to 13.5% compared to 12.4% in the first quarter of 2011.
• SG&A increased $0.7 million mainly due to higher non-cash charges for equity compensation.
• R&D expense increased to $9.4 million compared to $2.4 million in first quarter of 2011, due to accelerated Phase III clinical development.
• Net loss was ($10.6) million compared to a net loss of ($2.9) million in first quarter of 2011, due to higher R&D expense.
• Successful equity capital raise in February 2012 netted proceeds of approximately $16.2 million.
• Cash and investments aggregated $25.6 million as of March 31, 2012.

Current Drug Development Highlights

• PRIME study designed to capture ESA-sparing data completed enrollment.
• Phase III CRUISE efficacy studies nearing patient enrollment completion.
• Data Safety Monitoring Board recommended continuation of studies with no modifications after 2^nd review.
• Preparation for Calcitriol (vitamin-D) launch on track.
• Raymond D. Pratt, MD, hired as Chief Medical Officer.

Mr. Robert L. Chioini, Chairman and CEO, stated, “We are pleased to report to you our continued SFP clinical development progress, highlighted by the completion of enrollment in our PRIME study. We look forward to study completion in nine short months. Our Calcitriol product launch remains on target.” Mr. Chioini also stated, “First quarter operating performance was in line with our expectations. Both sales and margins increased over last quarter, despite rising fuel and material costs.”

Conference Call Information:

Rockwell Medical will be hosting a conference call to review its first quarter 2012 results on Thursday, May 3, 2012 at 8:30 am ET. Investors are encouraged to call a few minutes in advance at (877) 383-7438 or to listen to the call on the web at: http://ir.rockwellmed.com/

About Rockwell Medical:

Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. Rockwell’s lead drug candidate for iron therapy treatment is called SFP.  SFP delivers iron in a non-invasive, physiologic manner to dialysis patients via dialysate during their regular dialysis treatment.  SFP is currently in ongoing Phase III clinical trials (CRUISE-1 and CRUISE-2) and addresses a $600M U.S. market.  Rockwell’s Calcitriol (Active Vitamin D) injection for treating secondary hyperparathyroidism addresses a $350M U.S. market. 

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. These products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream.  Rockwell’s operating business is designed as a ready-made sales and distribution channel to provide seamless integration into the commercial market for its drug products, Calcitriol and SFP upon FDA market approval. 

Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience.  Rockwell Medical is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. For a demonstration of SFP’s unique mechanism of action in delivering iron via dialysate, please view the animation video at http://www.rockwellmed.com/collateral/documents/english-us/mode-of-action.html.

The Rockwell Medical Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6773

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to launch Calcitriol and SFP following FDA approval. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT: Michael Rice, Investor Relations

         (646) 597-6979

Source: Rockwell Medical Technologies, Inc.

Probability of Michigan Retirees Outliving Their Financial Assets

Source: www.paycheckforlife.org

We came across a recent study done by the prestigious Ernst & Young, LLC covered by Americans for Secure Retirement. (For a more in-depth look at the study, visit the website by clicking on the chart above.) The study found that almost three quarters of middle-income Michigan households seven years from retirement (near-retirees) can expect to outlive their financial assets if they attempt to maintain their pre-retirement standard of living. Obviously this does not uniformly apply to everyone as it is a sample of the population, but it is trying to show a current trend.

Another finding pointed out that near-retirees in Michigan would have to reduce their standard of living on average by 35% to reduce the likelihood of outliving their financial assets (failure rate) to only five percent. Although it is common belief that retired people have lower costs than their working counterparts, we have found from our clients that the idea more than likely isn’t the case and clients need to maintain their pre-retirement standard of living. Yes, retirees may have their home paid off, cars paid for and college bills out of the picture, but retirees also have more free time and are able to go out and do things like golfing or traveling more often then they did in the past. Then, as they age, they find they might have higher medical bills. So, what can you do to help cut expenses in retirement with the things you have control over? Here’s a great US News article that provides 21 different ideas to help you chop your spending: http://bit.ly/coypIj

We aren’t posting this to scare you with statistics. Although the outlook and findings may appear bleak, they also seem to point to the extremely important idea that pre-retirees and retirees should work with a qualified professional to create a financial plan as well as continue to revisit and update that plan on a regular basis. And even though making a plan is a great step – the hardest part is actually sticking to the plan. Having a qualified professional that knows you well and can hold you accountable is a great way to make sure you stay on track to help avoid outliving your assets, not to mention, maintain your peace of mind.

If you don’t currently have a plan or don’t work with a professional that acts as a coach to help you stick to your plan, give us a call! We’d be happy to see if we can be a future resource for you.